glp-1 receptor agonists and sglt2 inhibitors Complementary Yet Distinct Roles of in Cardiovascular Risk Reduction Blood Pressure-Lowering Effects of SGLT2

SaveHealth reports that Zepbound and Wegovy, both FDA-approved weight loss injectables, differ in mechanisms and efficacy

Therefore, further research is necessary to fully understand the potential of GLP-1 receptor agonists in providing comprehensive protection against complications related to T2DM.

FDA updates rules on compounded GLP-1 drugs, impacting patients and providers

Objective This systematic review aims to synthesise published evidence on respiratory adverse events temporally associated with GLP-1 RA therapy in adults, characterise their patterns and severity, appraise the risk of bias using validated design-appropriate tools, describe proposed pathophysiological mechanisms, and grade the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework

Materials and Methods This was a single centre retrospective observational study conducted at a Swiss bariatric reference centre

The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery